Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers

International Braz J Urol

Volumn 37, Issue 1, 2011, Pages 57-66

  Cindolo, L ^a   Cantile, M ^b   Franco, R ^c   Chiodini, P ^d   Schiavo, G ^e   Forte, I ^c   Zlobec, I ^e   Salzano, L ^f   Botti, G ^a   Gidaro, S ^g   Terracciano, L ^e   Cillo, C ^b,e  

^a S Pio da Pietrelcina Hospital   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF BASEL   (Switzerland)

^f G RUMMO HOSPITAL   (Italy)

^g UNIVERSITY OF CHIETI   (Italy)

Author keywords

Androgen prognosis; Chromogranin A; Ki 67 antigen; NeuroD1 protein; Neuroendocrine cells; Prostatic neoplasms; Receptors

Indexed keywords

ANDROGEN RECEPTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CHROMOGRANIN A; KI 67 ANTIGEN; NERVE PROTEIN; NEUROGENIC DIFFERENTIATION FACTOR; TUMOR MARKER;

AGED; ANALYSIS OF VARIANCE; ARTICLE; CANCER GRADING; CHEMISTRY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; SURVIVAL RATE; TIME; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHROMOGRANIN A; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NERVE TISSUE PROTEINS; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SURVIVAL RATE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955892655     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382011000100008     Document Type: Article

References (30)

1. Prostate Cancer Incidence and Mortality Worldwide in 2008: Globocan 2002. Available at http://globocan.iarc.fr/factsheets/cancers/prostate.asp Last access 11 Nov. 2010.
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al.: Edwards BK (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. Available at http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
3. Schröder FH: Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol. 2008; 53: 1129-37.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-12.
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-20.
6. Jiborn T, Bjartell A, Abrahamsson PA: Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology. 1998; 51: 585-9.
7. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N: Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004; 45: 586-92; discussion 592.
8. Kokubo H, Yamada Y, Nishio Y, Fukatsu H, Honda N, Nakagawa A, et al.: Immunohistochemical study of chromogranin A in Stage D2 prostate cancer. Urology. 2005; 66: 135-40.
9. Cindolo L, Cantile M, Vacherot F, Terry S, de la Taille A: Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int. 2007; 79: 287-96.
10. Vashchenko N, Abrahamsson PA: Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005; 47: 147-55.
11. Sciarra A, Gentile V, Monti S, Dattilo C, Gomez AA, Salciccia S, et al.: Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Urol Int. 2008; 80: 68-73.
12. Zitella A, Berruti A, Destefanis P, Mengozzi G, Torta M, Ceruti C, et al.: Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia. Clin Chim Acta. 2007; 377: 103-7.
13. Yamada Y, Nakamura K, Aoki S, Taki T, Matsubara H, Sai S, et al.: Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome? Oncol Rep. 2006; 15: 1309-13.
14. Cindolo L, Franco R, Cantile M, Schiavo G, Liguori G, Chiodini P, et al.: NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension? Eur Urol. 2007; 52: 1365-73.
15. Hvamstad T, Jordal A, Hekmat N, Paus E, Fosså SD: Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol. 2003; 44: 215-21.
16. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al.: Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer. 2000; 88: 2590-7.
17. Cantile M, Kisslinger A, Cindolo L, Schiavo G, D'Antò V, Franco R, et al.: cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers. J Cell Physiol. 2005; 205: 202-10.
18. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, et al.: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate. 2003; 55: 20-9.
19. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al.: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4: 844-7.
20. Abrahamsson PA, Wadström LB, Alumets J, Falkmer S, Grimelius L: Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract. 1986; 181: 675-83.
21. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al.: Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol. 2009; 16: 37-44.
22. Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, et al.: Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res. 2007; 27: 3651-60.
23. May M, Siegsmund M, Hammermann F, Loy V, Gunia S: Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol. 2007; 41: 375-81.
24. Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z, et al.: Pro-neural transcription factors as cancer markers. BMC Med Genomics. 2008; 1: 17.
25. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T: EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer. 2008; 122: 595-602.
26. Rubio J, Ramos D, López-Guerrero JA, Iborra I, Collado A, Solsona E, et al.: Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol. 2005; 48: 745-51.
27. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF: Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta. 2001; 1539: 28-43.
28. Yuan TC, Veeramani S, Lin MF: Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007; 14: 531-47.
29. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al.: Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol. 2009; 20: 703-8.
30. Hadaschik BA, Sowery RD, Gleave ME: Novel targets and approaches in advanced prostate cancer. Curr Opin Urol. 2007; 17: 182-7.